TP53 and hepatocellular carcinoma: Furthermore, consistent with data indicating that HCC with TP53 mutation is markedly associated with immunosuppression (67), it was confirmed that the C3 subgroup, which harbored the highest frequency of TP53 mutations, presented poorer response to immunotherapy.